Sex differences in Parkinson's disease

Frontiers in Neuroendocrinology

Volumn 35, Issue 3, 2014, Pages 370-384

  Gillies, Glenda E ^a   Pienaar, Ilse S ^a   Vohra, Shiv ^a   Qamhawi, Zahi ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Neuroprotection; Nigrostriatal dopaminergic pathways; Parkinson's disease; Sex differences; Sex hormones

Indexed keywords

ESTROGEN; SEX HORMONE; DOPAMINE; NEUROPROTECTIVE AGENT;

ASTROCYTE; BRAIN NERVE CELL; CELL SURVIVAL; CLINICAL FEATURE; DISEASE MODEL; DISEASE PREDISPOSITION; EARLY LIFE STRESS; EPIGENETICS; EXPERIMENTAL PARKINSONISM; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; GLIA CELL; HORMONE ACTION; HUMAN; LIFESTYLE; MICROGLIA; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SRY GENE; ANIMAL; DRUG EFFECTS; METABOLISM; SEXUAL DEVELOPMENT; SUBSTANTIA NIGRA;

ANIMALS; DOPAMINE; GONADAL STEROID HORMONES; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SEX CHARACTERISTICS; SUBSTANTIA NIGRA;

EID: 84903757648     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2014.02.002     Document Type: Review

References (215)

1. Abraham I.M., Herbison A.E. Major sex differences in non-genomic estrogen actions on intracellular signaling in mouse brain in vivo. Neuroscience 2005, 131:945-951.
2. Al-Sweidi S., Morissette M., Bourque M., Di Paolo T. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011, 61:583-591.
3. Alves G., Muller B., Herlofson K., HogenEsch I., Telstad W., Aarsland D., Tysnes O.B., Larsen J.P. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 2009, 80:851-857.
4. Arevalo M.A., Santos-Galindo M., Acaz-Fonseca E., Azcoitia I., Garcia-Segura L.M. Gonadal hormones and the control of reactive gliosis. Horm. Behav. 2013, 63:216-221.
5. Arnold A.P. The end of gonad-centric sex determination in mammals. Trends Genet. 2012, 28:55-61.
6. Arnold A.P., Breedlove S.M. Organizational and activational effects of sex steroids on brain and behavior: a reanalysis. Horm. Behav. 1985, 19:469-498.
7. Arnold A.P., Burgoyne P.S. Are XX and XY brain cells intrinsically different?. Trends Endocrinol. Metab. 2004, 15:6-11.
8. Auger A.P., Hexter D.P., McCarthy M.M. Sex difference in the phosphorylation of cAMP response element binding protein (CREB) in neonatal rat brain. Brain Res. 2001, 890:110-117.
9. Azcoitia I., Santos-Galindo M., Arevalo M.A., Garcia-Segura L.M. Role of astroglia in the neuroplastic and neuroprotective actions of estradiol. Eur. J. Neurosci. 2010, 32:1995-2002.
10. Baba Y., Putzke J.D., Whaley N.R., Wszolek Z.K., Uitti R.J. Gender and the Parkinson's disease phenotype. J. Neurol. 2005, 252:1201-1205.
11. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000, 55:1358-1363.
12. Baraka A.M., Korish A.A., Soliman G.A., Kamal H. The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease. Life Sci. 2011, 88:879-885.
13. Barlow B.K., Cory-Slechta D.A., Richfield E.K., Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod. Toxicol. 2007, 23:457-470.
14. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440.
15. Bassilana F., Mace N., Li Q., Stutzmann J.M., Gross C.E., Pradier L., Benavides J., Menager J., Bezard E. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol. Dis. 2005, 20:93-103.
16. Becker J.B. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 1999, 64:803-812.
17. Behl C. Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 2002, 3:433-442.
18. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 2001, 16:830-837.
19. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
20. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26:215-221.
21. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012, 2012:845618.
22. Blum D., Torch S., Lambeng N., Nissou M.-F., Benabid A.-L., Sadoul R., Verna J.-M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
23. Blurton-Jones M., Tuszynski M.H. Reactive astrocytes express estrogen receptors in the injured primate brain. J. Comp. Neurol. 2001, 433:115-123.
24. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Res. Brain Res. Rev. 2004, 45:1-17.
25. Boksa P., El-Khodor B.F. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci. Biobehav. Rev. 2003, 27:91-101.
26. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30:142-157.
27. Bourque M., Liu B., Dluzen D.E., Di Paolo T. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 2011, 36:955-969.
28. Bourque M., Dluzen D.E., Di Paolo T. Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways. Neuropharmacology 2012, 62:2363-2372.
29. Bourque M., Morissette M., Cote M., Soulet D., Di Paolo T. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol. Aging 2013, 34:887-901.
30. Brann D.W., Dhandapani K., Wakade C., Mahesh V.B., Khan M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007, 72:381-405.
31. Brinton R.D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008, 31:529-537.
32. Bronstein J., Carvey P., Chen H., Cory-Slechta D., DiMonte D., Duda J., English P., Goldman S., Grate S., Hansen J., Hoppin J., Jewell S., Kamel F., Koroshetz W., Langston J.W., Logroscino G., Nelson L., Ravina B., Rocca W., Ross G.W., Schettler T., Schwarzschild M., Scott B., Seegal R., Singleton A., Steenland K., Tanner C.M., Van Den Eeden S., Weisskopf M. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ. Health Perspect. 2009, 117:117-121.
33. Bruns J., Hauser W.A. The epidemiology of traumatic brain injury: a review. Epilepsia 2003, 44(Suppl. 10):2-10.
34. Cahill L. Why sex matters for neuroscience. Nat. Rev. Neurosci. 2006, 7:477-484.
35. Callier S., Le Saux M., Lhiaubet A.M., Di Paolo T., Rostene W., Pelaprat D. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture. J. Neurochem. 2002, 80:307-316.
36. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 2004, 101:9103-9108.
37. Cantuti-Castelvetri I., Keller-McGandy C., Bouzou B., Asteris G., Clark T.W., Frosch M.P., Standaert D.G. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol. Dis. 2007, 26:606-614.
38. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 1991, 553:275-283.
39. Carvey P.M., Punati A., Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006, 15:239-250.
40. Castaneda E., Whishaw I.Q., Robinson T.E. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J. Neurosci. 1990, 10:1847-1854.
41. Chen F.P., Chien M.H. Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells. Climacteric 2013.
42. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004, 18:1162-1164.
43. Chen J.Q., Cammarata P.R., Baines C.P., Yager J.D. Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochim. Biophys. Acta 2009, 1793:1540-1570.
44. Chung C.Y., Koprich J.B., Siddiqi H., Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci.: Off. J. Soc. Neurosci. 2009, 29:3365-3373.
45. Chung S.J., Armasu S.M., Biernacka J.M., Lesnick T.G., Rider D.N., Cunningham J.M., Maraganore D.M. Variants in estrogen-related genes and risk of Parkinson's disease. Mov. Disord. 2011, 26:1234-1242.
46. Ciesielska A., Joniec I., Kurkowska-Jastrzebska I., Cudna A., Przybylkowski A., Czlonkowska A., Czlonkowski A. The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm. Res. 2009, 58:747-753.
47. Clark A.J., Ritz B., Prescott E., Rod N.H. Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson's disease: a prospective cohort study. Eur. J. Neurol. 2013, 20:1113-1120.
48. Cordellini M.F., Piazzetta G., Pinto K.C., Delattre A.M., Matheussi F., Carolino R.O., Szawka R.E., Anselmo-Franci J.A., Ferraz A.C. Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease. Neurochem. Res. 2011, 36:955-961.
49. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 2004, 61:886-888.
50. Czech D.P., Lee J., Sim H., Parish C.L., Vilain E., Harley V.R. The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism. J. Neurochem. 2012, 122:260-271.
51. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999, 122(Pt 8):1421-1436.
52. Das K., Ghosh M., Nag C., Nandy S.P., Banerjee M., Datta M., Devi G., Chaterjee G. Role of familial, environmental and occupational factors in the development of Parkinson's disease. Neurodegener. Dis. 2011, 8:345-351.
53. Datla K.P., Murray H.E., Pillai A.V., Gillies G.E., Dexter D.T. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 2003, 14:47-50.
54. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283:9089-9100.
55. Dewing P., Chiang C.W., Sinchak K., Sim H., Fernagut P.O., Kelly S., Chesselet M.F., Micevych P.E., Albrecht K.H., Harley V.R., Vilain E. Direct regulation of adult brain function by the male-specific factor SRY. Curr. Biol. 2006, 16:415-420.
56. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 2013, 62:132-144.
57. Disshon K.A., Dluzen D.E. Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats. Brain Res. 2000, 868:95-104.
58. Dluzen D.E. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 1996, 715:113-118.
59. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997, 767:340-344.
60. Dluzen D.E. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J. Neurocytol. 2000, 29:387-399.
61. Dluzen D.E. Unconventional effects of estrogen uncovered. Trends Pharmacol. Sci. 2005, 26:485-487.
62. Dluzen D., Horstink M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 2003, 21:67-75.
63. Dluzen D.E., Liu B. Gender differences in methamphetamine use and responses: a review. Gend. Med. 2008, 5:24-35.
64. Dluzen D., Jain R., Liu B. Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurochem. 1994, 62:94-101.
65. Dluzen D.E., Anderson L.I., Pilati C.F. Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol. Teratol. 2002, 24:267-273.
66. Elbaz A., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 2002, 55:25-31.
67. Farina C., Aloisi F., Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007, 28:138-145.
68. Federman D.D. The biology of human sex differences. N. Engl. J. Med. 2006, 354:1507-1514.
69. Ferraz A.C., Xavier L.L., Hernandes S., Sulzbach M., Viola G.G., Anselmo-Franci J.A., Achaval M., Da Cunha C. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res. 2003, 986:200-205.
70. Ferraz A.C., Matheussi F., Szawka R.E., Rizelio V., Delattre A.M., Rigon P., Hermel Edo E., Xavier L.L., Achaval M., Anselmo-Franci J.A. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem. Res. 2008, 33:1238-1246.
71. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 2010, 184:133-157.
72. Gabory A., Attig L., Junien C. Sexual dimorphism in environmental epigenetic programming. Mol. Cell. Endocrinol. 2009, 304:8-18.
73. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 1997, 69:1322-1325.
74. Gao X., Dluzen D.E. The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res. 2001, 892:63-69.
75. Garcia-Ovejero D., Azcoitia I., Doncarlos L.L., Melcangi R.C., Garcia-Segura L.M. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res. Brain Res. Rev. 2005, 48:273-286.
76. Garcia-Segura L.M., Azcoitia I., DonCarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 2001, 63:29-60.
77. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. USA 2008, 105:11364-11369.
78. Gillies G.E., McArthur S. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm. Behav. 2010, 57:23-34.
79. Gillies G.E., McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 2010, 62:155-198.
80. Gillies G.E., Murray H.E., Dexter D., McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol. Biochem. Behav. 2004, 78:513-522.
81. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 1996, 66:2004-2010.
82. Gomez-Sintes R., Hernandez F., Lucas J.J., Avila J. GSK-3 mouse models to study neuronal apoptosis and neurodegeneration. Front. Mol. Neurosci. 2011, 4:45.
83. Green P.S., Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. Int. J. Dev. Neurosci. 2000, 18:347-358.
84. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., Booij J., Dluzen D.E., Horstink M.W. Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:819-824.
85. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., Nissbrandt H. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatry Genet. 2005, 133B:88-92.
86. Halassa M.M., Haydon P.G. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 2010, 72:335-355.
87. Halliday G.M., Stevens C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 2011, 26:6-17.
88. Hernandez-Baltazar D., Mendoza-Garrido M.E., Martinez-Fong D. Activation of GSK-3beta and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS ONE 2013, 8:e70951.
89. Jenner P., Morris H.R., Robbins T.W., Goedert M., Hardy J., Ben-Shlomo Y., Bolam P., Burn D., Hindle J.V., Brooks D. Parkinson's disease - the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J. Parkinsons Dis. 2013, 3:1-11.
90. Jennings P.J., Janowsky J.S., Orwoll E. Estrogen and sequential movement. Behav. Neurosci. 1998, 112:154-159.
91. Ji J., Dluzen D.E. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice. J. Neural Transm. 2008, 115:809-817.
92. Kaasinen V., Nagren K., Hietala J., Farde L., Rinne J.O. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am. J. Psychiatry 2001, 158:308-311.
93. Kaminsky Z., Wang S.C., Petronis A. Complex disease, gender and epigenetics. Ann. Med. 2006, 38:530-544.
94. Kipp M., Karakaya S., Johann S., Kampmann E., Mey J., Beyer C. Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J. Neuroendocrinol. 2007, 19:819-822.
95. Klegeris A., McGeer E.G., McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 2007, 20:351-357.
96. Klein L.C., Corwin E.J. Seeing the unexpected: how sex differences in stress responses may provide a new perspective on the manifestation of psychiatric disorders. Curr. Psychiatry Rep. 2002, 4:441-448.
97. Klein C., Schlossmacher M.G. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007, 69:2093-2104.
98. Klink R., Robichaud M., Debonnel G. Gender and gonadal status modulation of dorsal raphe nucleus serotonergic neurons. Part II. Regulatory mechanisms. Neuropharmacology 2002, 43:1129-1138.
99. Kritzer M.F., Creutz L.M. Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats. J. Neurosci. 2008, 28:9525-9535.
100. Kudielka B.M., Kirschbaum C. Sex differences in HPA axis responses to stress: a review. Biol. Psychol. 2005, 69:113-132.
101. Kuo J., Hamid N., Bondar G., Dewing P., Clarkson J., Micevych P. Sex differences in hypothalamic astrocyte response to estradiol stimulation. Biol. Sex Differ. 2010, 1:7.
102. Kuppers E., Ivanova T., Karolczak M., Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol. 2000, 29:375-385.
103. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9:349-372.
104. Laakso A., Vilkman H., Bergman J., Haaparanta M., Solin O., Syvalahti E., Salokangas R.K., Hietala J. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol. Psychiatry 2002, 52:759-763.
105. 123I]FP-CIT SPET in healthy volunteers. Eur. J. Nucl. Med. 2000, 27:867-869.
106. Lehman E.J., Hein M.J., Baron S.L., Gersic C.M. Neurodegenerative causes of death among retired National Football League players. Neurology 2012, 79:1970-1974.
107. Lewis C., Dluzen D.E. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci. Lett. 2008, 448:130-133.
108. Ling Z.D., Chang Q., Lipton J.W., Tong C.W., Landers T.M., Carvey P.M. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004, 124:619-628.
109. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34:555-565.
110. Liu X., Fan X.L., Zhao Y., Luo G.R., Li X.P., Li R., Le W.D. Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. J. Neurosci. Res. 2005, 81:653-665.
111. Liu M., Hurn P.D., Roselli C.E., Alkayed N.J. Role of P450 aromatase in sex-specific astrocytic cell death. J. Cereb. Blood Flow Metab. 2007, 27:135-141.
112. Lucas S.M., Rothwell N.J., Gibson R.M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 2006, 147(Suppl. 1):S232-S240.
113. Lundblad M., Decressac M., Mattsson B., Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. USA 2012, 109:3213-3219.
114. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009, 10:434-445.
115. Macht M., Schwarz R., Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta Neurol. Scand. 2005, 111:95-101.
116. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
117. Maraganore D.M., Farrer M.J., McDonnell S.K., Elbaz A., Schaid D.J., Hardy J.A., Rocca W.A. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Mov. Disord. 2002, 17:509-512.
118. Marchetti B., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Cioni S., Gennuso F., Rocchitta G., Desole M.S., Mazzarino M.C., Miele E., Morale M.C. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann. N. Y. Acad. Sci. 2005, 1057:296-318.
119. Marien M.R., Colpaert F.C., Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 2004, 45:38-78.
120. Marsden C.D., Jenner P.G. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Ciba Found. Symp. 1987, 126:239-256.
121. Martinez-Martin P., Falup Pecurariu C., Odin P., van Hilten J.J., Antonini A., Rojo-Abuin J.M., Borges V., Trenkwalder C., Aarsland D., Brooks D.J., Ray Chaudhuri K. Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J. Neurol. 2012, 259:1639-1647.
122. Mattson M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid. Redox Signal. 2006, 8:1997-2006.
123. McArthur S., Gillies G.E. Peripheral vs. central sex steroid hormones in experimental Parkinson's disease. Front. Endocrinol. (Lausanne) 2011, 2:82.
124. McArthur S., McHale E., Gillies G.E. The size and distribution of midbrain dopaminergic populations are permanently altered by perinatal glucocorticoid exposure in a sex- region- and time-specific manner. Neuropsychopharmacology 2007, 32:1462-1476.
125. McArthur S., Murray H.E., Dhankot A., Dexter D.T., Gillies G.E. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. J. Neurochem. 2007, 100:678-692.
126. McArthur S., Cristante E., Paterno M., Christian H., Roncaroli F., Gillies G.E., Solito E. Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. J. Immunol. 2010, 185:6317-6328.
127. McCarthy M.M. Estradiol and the developing brain. Physiol. Rev. 2008, 88:91-124.
128. McCarthy M.M., Auger A.P., Bale T.L., De Vries G.J., Dunn G.A., Forger N.G., Murray E.K., Nugent B.M., Schwarz J.M., Wilson M.E. The epigenetics of sex differences in the brain. J. Neurosci.: Off. J. Soc. Neurosci. 2009, 29:12815-12823.
129. McDermott J.L., Liu B., Dluzen D.E. Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp. Neurol. 1994, 125:306-311.
130. McEwen B.S., Alves S.E. Estrogen actions in the central nervous system. Endocr. Rev. 1999, 20:279-307.
131. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
132. Mendez P., Azcoitia I., Garcia-Segura L.M. Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms. J. Endocrinol. 2005, 185:11-17.
133. Merchenthaler I., Lane M.V., Numan S., Dellovade T.L. Distribution of estrogen receptor alpha and beta in the mouse central nervous system: in vivo autoradiographic and immunocytochemical analyses. J. Comp. Neurol. 2004, 473:270-291.
134. Miller I.N., Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov. Disord. 2011, 25:2695-2703.
135. Miller D.B., Ali S.F., O'Callaghan J.P., Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 1998, 844:153-165.
136. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 1999, 20:424-429.
137. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18:315-321.
138. Mirzatoni A., Spence R.D., Naranjo K.C., Saldanha C.J., Schlinger B.A. Injury-induced regulation of steroidogenic gene expression in the cerebellum. J. Neurotrauma 2010, 27:1875-1882.
139. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., Pfaff D.W., Ogawa S., Rohrer S.P., Schaeffer J.M., McEwen B.S., Alves S.E. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144:2055-2067.
140. Morale M.C., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006, 138:869-878.
141. Morissette M., Di Paolo T. Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys. J. Neurosci. Res. 2009, 87:1634-1644.
142. Moroz I.A., Rajabi H., Rodaros D., Stewart J. Effects of sex and hormonal status on astrocytic basic fibroblast growth factor-2 and tyrosine hydroxylase immunoreactivity after medial forebrain bundle 6-hydroxydopamine lesions of the midbrain dopamine neurons. Neuroscience 2003, 118:463-476.
143. Mozley L.H., Gur R.C., Mozley P.D., Gur R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am. J. Psychiatry 2001, 158:1492-1499.
144. Munro C.A., McCaul M.E., Wong D.F., Oswald L.M., Zhou Y., Brasic J., Kuwabara H., Kumar A., Alexander M., Ye W., Wand G.S. Sex differences in striatal dopamine release in healthy adults. Biol. Psychiatry 2006, 59:966-974.
145. Murray H.E., Pillai A.V., McArthur S.R., Razvi N., Datla K.P., Dexter D.T., Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003, 116:213-222.
146. Nadkarni S., McArthur S. Oestrogen and immunomodulation: new mechanisms that impact on peripheral and central immunity. Curr. Opin. Pharmacol. 2013, 13:576-581.
147. Naftolin F., Garcia-Segura L.M., Horvath T.L., Zsarnovszky A., Demir N., Fadiel A., Leranth C., Vondracek-Klepper S., Lewis C., Chang A., Parducz A. Estrogen-induced hypothalamic synaptic plasticity and pituitary sensitization in the control of the estrogen-induced gonadotrophin surge. Reprod. Sci. 2007, 14:101-116.
148. Ngun T.C., Ghahramani N., Sanchez F.J., Bocklandt S., Vilain E. The genetics of sex differences in brain and behavior. Front. Neuroendocrinol. 2011, 32:227-246.
149. Ohtani H., Nomoto M., Douchi T. Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats. Brain Res. 2001, 900:163-168.
150. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674.
151. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., Schwarz G., Altmann H., Klewer M., Schoor M., Vonk R., Fritzemeier K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod. 2009, 80:34-41.
152. Palacios N., Weisskopf M., Simon K., Gao X., Schwarzschild M., Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism Relat. Disord. 2011, 16:370-375.
153. Papkovskaia T.D., Chau K.Y., Inesta-Vaquera F., Papkovsky D.B., Healy D.G., Nishio K., Staddon J., Duchen M.R., Hardy J., Schapira A.H., Cooper J.M. G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum. Mol. Genet. 2012, 21:4201-4213.
154. Pasqualini C., Olivier V., Guibert B., Frain O., Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem. 1995, 65:1651-1657.
155. Phani S., Loike J.D., Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1). S207-9.
156. Pienaar I.S., Chinnery P.F. Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression. Pharmacol. Ther. 2013, 137:1-21.
157. Pienaar I.S., Kellaway L.A., Russell V.A., Smith A.D., Stein D.J., Zigmond M.J., Daniels W.M. Maternal separation exaggerates the toxic effects of 6-hydroxydopamine in rats: implications for neurodegenerative disorders. Stress 2008, 11:448-456.
158. Pienaar I.S., Lu B., Schallert T. Closing the gap between clinic and cage: sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease. Neurosci. Biobehav. Rev. 2012, 36:2305-2324.
159. Pohjalainen T., Rinne J.O., Nagren K., Syvalahti E., Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am. J. Psychiatry 1998, 155:768-773.
160. Pons D.G., Nadal-Serrano M., Del Mar Blanquer-Rossello M., Sastre-Serra J., Oliver J., Roca P. Genistein modulates proliferation and mitochondrial functionality in breast cancer cells depending on ERalpha/ERbeta ratio. J. Cell. Biochem. 2013.
161. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., Leimpeter A., Nelson L.M. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005, 65:383-390.
162. Prossnitz E.R., Arterburn J.B., Smith H.O., Oprea T.I., Sklar L.A., Hathaway H.J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol. 2008, 70:165-190.
163. Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev. Neurobiol. 2008, 68:632-644.
164. Quinn N.P., Marsden C.D. Menstrual-related fluctuations in Parkinson's disease. Mov. Disord. 1986, 1:85-87.
165. Ragonese P., D'Amelio M., Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann. N. Y. Acad. Sci. 2006, 1089:373-382.
166. Ramirez A.D., Liu X., Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003, 77:223-231.
167. Raz L., Khan M.M., Mahesh V.B., Vadlamudi R.K., Brann D.W. Rapid estrogen signaling in the brain. Neurosignals 2008, 16:140-153.
168. Riccardi P., Park S., Anderson S., Doop M., Ansari M.S., Schmidt D., Baldwin R. Sex differences in the relationship of regional dopamine release to affect and cognitive function in striatal and extrastriatal regions using positron emission tomography and [(1)(8)F]fallypride. Synapse 2011, 65:99-102.
169. Robinson T.E., Castaneda E., Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can. J. Psychol. 1990, 44:253-275.
170. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., Melton L.J. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 70:200-209.
171. Rodriguez-Navarro J.A., Gomez A., Rodal I., Perucho J., Martinez A., Furio V., Ampuero I., Casarejos M.J., Solano R.M., de Yebenes J.G., Mena M.A. Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice. Hum. Mol. Genet. 2008, 17:3128-3143.
172. Rodriguez-Navarro J.A., Solano R.M., Casarejos M.J., Gomez A., Perucho J., de Yebenes J.G., Mena M.A. Gender differences and estrogen effects in parkin null mice. J. Neurochem. 2008, 106:2143-2157.
173. Rogers J., Mastroeni D., Leonard B., Joyce J., Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int. Rev. Neurobiol. 2007, 82:235-246.
174. Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int. J. Neurosci. 1989, 45:119-122.
175. Santos-Galindo M., Acaz-Fonseca E., Bellini M.J., Garcia-Segura L.M. Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biol. Sex Differ. 2011, 2:7.
176. Saunders-Pullman R., Gordon-Elliott J., Parides M., Fahn S., Saunders H.R., Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52:1417-1421.
177. Schrag A., Ben-Shlomo Y., Quinn N.P. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000, 321:21-22.
178. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 1996, 50:275-331.
179. Schwarz J.M., Bilbo S.D. Sex, glia, and development: interactions in health and disease. Horm. Behav. 2012, 62:243-253.
180. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42:1328-1335.
181. Serova L.I., Maharjan S., Huang A., Sun D., Kaley G., Sabban E.L. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res. 2004, 1015:1-8.
182. Shughrue P.J. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 2004, 190:468-477.
183. Shulman L.M., Bhat V. Gender disparities in Parkinson's disease. Expert Rev. Neurother. 2006, 6:407-416.
184. Simola N., Morelli M., Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 2007, 11:151-167.
185. Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS ONE 2011, 5:e8856.
186. Song D.D., Haber S.N. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J. Neurosci. 2000, 20:5102-5114.
187. Sundar Boyalla S., Barbara Victor M., Roemgens A., Beyer C., Arnold S. Sex- and brain region-specific role of cytochrome c oxidase in 1-methyl-4-phenylpyridinium-mediated astrocyte vulnerability. J. Neurosci. Res. 2011, 89:2068-2082.
188. Swerdlow R.H., Parker W.D., Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., Wooten G.F. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat. Disord. 2001, 7:129-133.
189. Tamas A., Lubics A., Szalontay L., Lengvari I., Reglodi D. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behav. Brain Res. 2005, 158:221-229.
190. Taylor K.S., Cook J.A., Counsell C.E. Heterogeneity in male to female risk for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:905-906.
191. Thanky N.R., Son J.H., Herbison A.E. Sex differences in the regulation of tyrosine hydroxylase gene transcription by estrogen in the locus coeruleus of TH9-LacZ transgenic mice. Mol. Brain Res. 2002, 104:220-226.
192. Tsang K.L., Ho S.L., Lo S.K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000, 54:2292-2298.
193. Vadasz C., Baker H., Fink S.J., Reis D.J. Genetic effects and sexual dimorphism in tyrosine hydroxylase activity in two mouse strains and their reciprocal F1 hybrids. J. Neurogenet. 1985, 2:219-230.
194. Vadasz C., Kobor G., Kabai P., Sziraki I., Vadasz I., Lajtha A. Perinatal anti-androgen treatment and genotype affect the mesotelencephalic dopamine system and behavior in mice. Horm. Behav. 1988, 22:528-539.
195. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
196. van Nas A., Guhathakurta D., Wang S.S., Yehya N., Horvath S., Zhang B., Ingram-Drake L., Chaudhuri G., Schadt E.E., Drake T.A., Arnold A.P., Lusis A.J. Elucidating the role of gonadal hormones in sexually dimorphic gene coexpression networks. Endocrinology 2009, 150:1235-1249.
197. Vegeto E., Benedusi V., Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 2008, 29:507-519.
198. Virdee K., McArthur S., Brischoux F., Caprioli D., Ungless M.A., Robbins T.W., Dalley J.W., Gillies G.E. Antenatal glucocorticoid treatment induces adaptations in adult midbrain dopamine neurons which underpin sexually dimorphic behavioral resilience. Neuropsychopharmacology 2013.
199. Vives-Bauza C., Tocilescu M., Devries R.L., Alessi D.M., Jackson-Lewis V., Przedborski S. Control of mitochondrial integrity in Parkinson's disease. Prog. Brain Res. 2010, 183:99-113.
200. Vohra, S., McArthur, S., Solito, E., Gillies, G., 2012. ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells. In: Society for Endocrinology, British Endocrine Society Annual Conference, Endocrine Abstracts, Harrogate, pp. OC 2.4.
201. Walker Q.D., Rooney M.B., Wightman R.M., Kuhn C.M. Dopamine release and uptake are greater in female than male rat striatum as measured by fast cyclic voltammetry. Neuroscience 2000, 95:1061-1070.
202. Wang J., Korczykowski M., Rao H., Fan Y., Pluta J., Gur R.C., McEwen B.S., Detre J.A. Gender difference in neural response to psychological stress. Soc. Cogn. Affect Neurosci. 2007, 2:227-239.
203. Wang S., Yan J.Y., Lo Y.K., Carvey P.M., Ling Z. Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res. 2009, 1265:196-204.
204. Weintraub D., Comella C.L., Horn S. Parkinson's disease - part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manage. Care 2008, 14:S40-S48.
205. Westberg L., Hakansson A., Melke J., Shahabi H.N., Nilsson S., Buervenich S., Carmine A., Ahlberg J., Grundell M.B., Schulhof B., Klingborg K., Holmberg B., Sydow O., Olson L., Johnels E.B., Eriksson E., Nissbrandt H. Association between the estrogen receptor beta gene and age of onset of Parkinson's disease. Psychoneuroendocrinology 2004, 29:993-998.
206. Whitworth S.R., Loftus A.M., Skinner T.C., Gasson N., Barker R.A., Bucks R.S., Thomas M.G. Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies. J. Parkinsons Dis. 2013, 3:45-53.
207. Wilson C.A., Davies D.C. The control of sexual differentiation of the reproductive system and brain. Reproduction 2007, 133:331-359.
208. Wise P.M., Dubal D.B., Wilson M.E., Rau S.W., Liu Y. Estrogens: trophic and protective factors in the adult brain. Front. Neuroendocrinol. 2001, 22:33-66.
209. Wise P.M., Dubal D.B., Rau S.W., Brown C.M., Suzuki S. Are estrogens protective or risk factors in brain injury and neurodegeneration? Reevaluation after the Women's health initiative. Endocr. Rev. 2005, 26:308-312.
210. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 2004, 75:637-639.
211. Xiao L., Becker J.B. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse 1998, 29:379-391.
212. Yu L., Liao P.C. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J. Neural Transm. 2000, 107:419-427.
213. Yu L., Liao P.C. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J. Neural Transm. 2000, 107:1139-1147.
214. Yu Y.L., Wagner G.C. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J. Neural Transm. Park. Dis. Dement. Sect. 1994, 8:215-221.
215. Yu L., Kuo Y., Cherng C.G., Chen H.H., Hsu C.H. Ovarian hormones do not attenuate methamphetamine-induced dopaminergic neurotoxicity in mice gonadectomized at 4 weeks postpartum. Neuroendocrinology 2002, 75:282-287.